The changing face of antibiotic prescribing: The mutant selection window

被引:38
作者
Epstein, BJ
Gums, JG
Drlica, K
机构
[1] Univ Florida, Coll Pharm, Dept Pharm Practice, Gainesville, FL 32601 USA
[2] Univ Florida, Coll Pharm, Dept Community Hlth & Family Med, Gainesville, FL 32601 USA
[3] Univ Florida, Coll Med, Dept Community Hlth & Family Med, Gainesville, FL 32601 USA
[4] Univ Florida, Coll Med, Dept Pharm Practice, Gainesville, FL 32601 USA
[5] N Florida S Georgia Vet Affairs Hlth Syst, Gainesville, FL USA
[6] Publ Hlth Res Inst, Newark, NJ USA
关键词
antimicrobial resistance; mutant prevention concentration; mutant selection window;
D O I
10.1345/aph.1E041
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To describe the mutant selection window, discuss supporting evidence and limitations, and suggest potential applications for clinical practice. DATA SOURCES: A MEDLINE search (1990-December 2003) of the English-language literature was conducted using the key words antibiotic, antimicrobial, resistance, mutant, selection window, prevention, MPC, and MSW in various combinations. Original investigations and reviews evaluating the mutant selection window, including abstracts and proceedings, were considered for inclusion. Published articles were also cross-referenced, and experts were contacted to locate additional pertinent data. STUDY SELECTION AND DATA EXTRACTION: All data sources identified were evaluated and all information deemed relevant was included. DATA SYNTHESIS: Until recently, physicians have had few ways to preserve antimicrobials from resistance other than by prescribing the agents less often. The mutant selection window hypothesis may modify this paradigm by shifting the focus to dosing strategies that reduce the growth of resistant mutants. Conventional dosing strategies have been formulated on the likelihood of curing an individual patient. Unfortunately, doses that cure patients appear to enrich resistant subpopulations of bacteria, thus promoting resistance. Antimicrobial-pathogen combinations can be identified that minimize mutant selection and cure patients while possibly restricting the progression of resistance. CONCLUSIONS: The mutant selection window hypothesis provides a framework for considering the contribution of dosing to resistance, and it offers ideas for restricting the enrichment of resistant mutants and antimicrobial resistance.
引用
收藏
页码:1675 / 1682
页数:8
相关论文
共 65 条
[51]   Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria [J].
Sindelar, G ;
Zhao, XL ;
Liew, A ;
Dong, YZ ;
Lu, T ;
Zhou, JF ;
Domagala, J ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (12) :3337-3343
[52]   Stretching the mutant prevention concentration (MPC) beyond its limits [J].
Smith, HJ ;
Nichol, KA ;
Hoban, DJ ;
Zhanel, GG .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (06) :1323-1325
[53]   Predominant pathogens found in the European prevalence of infection in intensive care study [J].
Spencer, RC .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1996, 15 (04) :281-285
[54]   Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone [J].
Sullivan, JT ;
Woodruff, M ;
Lettieri, J ;
Agarwal, V ;
Krol, GJ ;
Leese, PT ;
Watson, S ;
Heller, AH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (11) :2793-2797
[55]   Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States:: Results from the TRUST Surveillance Program, 1999-2000 [J].
Thornsberry, C ;
Sahm, DF ;
Kelly, LJ ;
Critchley, IA ;
Jones, ME ;
Evangelista, AT ;
Karlowsky, JA .
CLINICAL INFECTIOUS DISEASES, 2002, 34 :S4-S16
[56]  
*US DEP HHS, 1999, AGGR DAT NAT NOS INF
[57]   Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid [J].
Vernon, A ;
Burman, W ;
Benator, D ;
Khan, A ;
Bozeman, L .
LANCET, 1999, 353 (9167) :1843-1847
[58]   Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies [J].
Zhao, XL ;
Drlica, K .
CLINICAL INFECTIOUS DISEASES, 2001, 33 :S147-S156
[59]   Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus [J].
Zhao, XL ;
Eisner, W ;
Perl-Rosenthal, N ;
Kreiswirth, B ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (03) :1023-1027
[60]   Restricting the selection of antibiotic-resistant mutant bacteria: Measurement and potential use of the mutant selection window [J].
Zhao, XL ;
Drlica, K .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (04) :561-565